Developing innovative drugs through the commons Lessons from the DNDi experience - Archive ouverte HAL Access content directly
Preprints, Working Papers, ... Year : 2019

Developing innovative drugs through the commons Lessons from the DNDi experience

Abstract

In this paper we argue that DNDi, even though it belongs to the family of Product Development Partnerships (PDPs) created at the end of the 20th century, has followed a very particular trajectory, that allows us to characterize it as a distinctive commons in the field of public health. We illustrate this view by focusing on two features: DNDi’s promotion of collaborative platforms and its innovative intellectual property policy.
Fichier principal
Vignette du fichier
WP 33 DNDi as Commons.pdf (242.8 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03408089 , version 1 (28-10-2021)

Licence

Attribution - ShareAlike

Identifiers

  • HAL Id : hal-03408089 , version 1

Cite

Benjamin Coriat, P. Abécassis, J-F Alessandrini, Nathalie Coutinet, Stéphanie Leyronas. Developing innovative drugs through the commons Lessons from the DNDi experience. 2019. ⟨hal-03408089⟩
88 View
46 Download

Share

Gmail Facebook X LinkedIn More